DGAP-Adhoc: Eckert & Ziegler Acquires Argentinian SPECT Specialist
|
DGAP-Ad-hoc: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Takeover/Strategic Company Decision Berlin, 3 January 2022. Eckert & Ziegler has acquired 100% of the shares of Argentinian nuclear medicine specialist Tecnonuclear S. A., a manufacturer of Technetium-99 generators and a portfolio of related biomolecules. These so-called "cold kits" function as vectors for the in-vivo delivery of Technetium-99 to more specific biological targets such as receptors and transporters. In tandem with the generators these generic tracers are commonly also referred to as SPECT diagnostics. Worldwide they represent the most widely used class of nuclear medicine products for the detection of cancer and cardio-vascular abnormalities at all. Based in Buenos Aires, Tecnonuclear employs a staff of 60 and in 2021 booked revenues of about 10 million USD. Its products have already been distributed in the past by Eckert & Ziegler in Brazil, where they are sold, together with the generators, as consumables for single-photon emission computerized tomography (as the acronym SPECT is spelled out). Even though Tecnonuclear has managed to keep a substantial share of the value creation for SPECT biomolecules in-house, the company's products, up until now, have not been sold outside Latin America. The purchase price was primarily based on Tecnonuclear's earnings power and completely paid out of Eckert & Ziegler's cash flow. No third-party financing was involved in the transaction.
Information and Explanation of the Issuer to this News: 'Together with Eckert & Ziegler's global network of productions sites, it's financial resources and expertise in the production and marketing of radioisotopes, Tecnonuclear is ideally positioned to serve as an entry ticket into the global SPECT market', comments Frank Yeager, the member of the Group Executive Committee at Eckert & Ziegler responsible for the SPECT business. 'Our plan is to bring the technology developed in Argentina to patients anywhere in the world'. 'The acquisition allows us also to extend critical healthcare in Brazil, in line with recent government actions there, and throughout South America', adds Claudia Goulart, CEO of Eckert & Ziegler's Latin American operations. 'This will make it possible to support the regional healthcare establishments in world class research, development and patient care'. Currently about 25 million patients per year benefit from SPECT-diagnostics, bringing the global market to a volume of about 1.7 billion USD. With the advent of new proprietary SPECT tracers demand is projected to expand dynamically, surpassing a volume of about 2.7 billion USD in 2027. Except for a small sales volume in Brazil, Eckert & Ziegler currently has not been active in the SPECT segment. About Eckert & Ziegler
03-Jan-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | [email protected] |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1264363 |
| End of Announcement | DGAP News Service |
|
|
1264363 03-Jan-2022 CET/CEST
Eckert & Ziegler Strahlen- und Medizintechnik AG Aktie
Eine klare Tendenz zu Buy-Einschätzungen bei Eckert & Ziegler Strahlen- und Medizintechnik AG, ohne Sell-Einschätzungen.
Das Kursziel von 95 € für Eckert & Ziegler Strahlen- und Medizintechnik AG übertrifft den aktuellen Kurs von 46.68 € um mehr als das Doppelte.
